See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Research Videos on Diabetes Health TV

Medtronic Diabetes

Courtney Parkin

Medtronic Diabetes

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

New Small Molecule Drugs for Type 2 - Human Trials Underway

Christoph Westphal, MD, Ph.D

New Small Molecule Drugs for Type 2 - Human Trials Underway

FDA Archives

FDA

Page 2
Social Media, Partnerships Are Top Topics at AADE12

As diabetes climbs to epidemic levels in the United States, and finding adequate resources to fund future U.S. healthcare remains in question, the need for an already existing "boots on the ground" group that can address the disease is greater than ever.

Comments 0 comments - Aug 15, 2012 - * * * * *

Type 1: New Drug Class Could Lead to Neuropathy Relief

University of California researchers report that they have found a new class of drugs that could lead to a pain relief treatment for people who have diabetic neuropathy. The drugs, which were successfully tested on lab animals, are anti-inflammatory compounds that inhibit the action of an enzyme called soluble epoxide hydrolase. The enzyme is key to the transmission of pain sensations. Previous research has shown that inhibiting soluble epoxide hydrolase also lowers blood pressure and protects against kidney damage.

Comments 0 comments - Jul 7, 2012 - * * * * *

ADA Sessions Spotlight Powerful Weapons Against Diabetes

Several hopeful trends emerged from this year's ADA Scientific Sessions in Philadelphia, held June 8 through 12.

Comments 0 comments - Jun 23, 2012 - * * * * *

When Medical Devices Fail

Medical devices aren't just any old pieces of technology. Lives depend upon them. For that reason, the government outlined a process decades ago by which manufacturers and importers were supposed to report malfunctions. But there was one problem: When malfunctions occurred, the manufacturers and importers did not admit it. According to the Food and Drug Administration, "A 1986 General Accounting Office (GAO) study showed that less than one percent of device problems occurring in hospitals are reported to FDA, and the more serious the problem with a device, the less likely it was to be reported."

Comments 0 comments - Jun 22, 2012 - * * * * *

Dexcom Proudly Sponsors Historic Diabetes Flight Formation Trip To Raise Juvenile Diabetes Research Foundation Funds Dexcom Proudly Sponsors Historic Diabetes Flight Formation Trip To Raise Juvenile Diabetes Research Foundation Funds

SAN DIEGO - June 15, 2012 - Dexcom, the leader in continuous glucose monitoring, is proudly sponsoring the efforts of the Diabetes Formation Flight USA(DFFUSA.org) - three pilots with insulin-dependent diabetes using Dexcom's Seven Plus as part of their effort to set new transcontinental world speed records while raising funds for the Juvenile Diabetes Research Foundation (JDRF).

Comments 0 comments - Jun 20, 2012 - * * * * *

Type 1: FDA OKs Levemir for Two- to Five-Year-Olds

The US Food and Drug Administration has approved the use of Novo Nordisk's Levemir basal insulin for type 1 children aged two to five years. The FDA decision makes Levemir (insulin detemir [rDNA origin]) the only basal insulin approved for use in this age group.
Levemir, introduced to the US market in 2006, was previously approved for older children and adults with type 1 diabetes, as well as insulin-using type 2s.

Comments 0 comments - Jun 7, 2012 - * * * * *

Insulin degludec

Novo Nordisk's new variety of long-lasting insulin, insulin degludec, reduces low blood sugars while improving overall control, according to a pair of studies published in the prestigious journal The Lancet on April 27.

Comments 0 comments - May 8, 2012 - * * * * *

FDA Warns Diabetes Patients About Combining Aliskiren

On April 19, the US Food and Drug Administration issued a warning to diabetes patients not to combine the blood pressure medication aliskiren (Tekturna) with ACE inhibitors or angiotensin receptor blockers. The warning also applies to patients who have renal impairment.

Comments 0 comments - Apr 30, 2012 - * * * * *

FDA Gives Go-ahead to Bayer’s CONTOUR® Next EZ

The US Food and Drug Administration has okayed US sales of Bayer HealthCare's CONTOUR® Next EZ blood glucose monitoring system. The new BGM, currently available in other countries as the CONTOUR XT, will be available in the US market this summer.

Comments 0 comments - Apr 25, 2012 - * * * * *

Neuropathy Device Maker Files

NeuroMetrix, Inc., a Massachusetts-based medical device company, has filed a 510(k) form with the US Food and Drug Administration for the SENSUSTM, a pain therapy device for people who suffer diabetic neuropathy. A 510(k) is a "premarket notification" of a company's intent to market a medical product. The FDA then tests the product and provides feedback to the manufacturer. Once the FDA clears the product, its maker can introduce it to the US market.

Comments 0 comments - Apr 24, 2012 - * * * * *

Next Page » « Previous Page
©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.